Neffy nasal spray shows comparable efficacy to IM epinephrine for type I allergic reactions, with 92.3% symptom resolution after 1 dose.
Real-world data from 2016 to 2025 highlight the changing landscape of biologic use and the growing preference for tezepelumab in asthma.
Writing a dissertation or a literary review is not the same as weaving a creative tale fueled by your imagination. Academic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results